NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in RRMM Myeloma (IMMUNICY-1)
Updated: Feb 10
NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (IMMUNICY-1)
Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (IMMUNICY-1)
The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide
Sponsor
ClinicalTrials.gov Identifier: NCT04613557
Official Title: Open-label Phase I, Multi-center Study to Determine the Recommended Dose of CYAD-211 After a Non-myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients With Relapsed or Refractory Disease
First Posted : November 3, 2020
Click here to see details on ClinicalTrials.gov
Biological: CYAD-211
Drug: Endoxan
Drug: Fludara
Allogeneic shRNA-based Anti-BCMA CAR T-cells CYAD-211 (Code C176885)
Allogeneic shRNA-based Anti-BCMA CAR T-cells CYAD-211
Allogeneic shRNA-based Anti-BCMA CAR-T Cells CYAD-211
CYAD 211
CYAD-211
CYAD211
Locations
United States, Florida
United States, New York
Europe
Belgium